Related Experiment Video
Updated: Jul 5, 2026

06:59
Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test
Published on: November 13, 2016
Hyperglucagonemia of renal failure
The Journal of Clinical Investigation
|March 1, 1974
Summary
Patients with chronic renal failure (CRF) show abnormal glucose and insulin responses. Elevated plasma glucagon levels persist even after hemodialysis, suggesting impaired glucagon regulation in CRF.
Area of Science:
- Endocrinology
- Nephrology
- Metabolic research
Background:
- Elevated plasma glucagon is linked to catabolic states like diabetes and infections.
- Understanding glucagon's role in chronic renal failure (CRF) is crucial for metabolic management.
Purpose of the Study:
- To investigate plasma glucose, insulin, and glucagon responses in CRF patients.
- To assess the impact of a beef meal and intravenous glucose on these hormones.
- To evaluate the effect of chronic hemodialysis on hormonal responses in CRF.
Main Methods:
- Assessed plasma glucose, immunoreactive insulin (IRI), and immunoreactive glucagon (IRG) levels.
- Administered a beef meal (1 g/kg body weight) and intravenous glucose infusion (1.5 g/min for 45 min).
- Compared responses in CRF patients before and after 6 weeks of hemodialysis against control subjects.
Main Results:
- CRF patients exhibited unchanged plasma glucose but increased IRI and IRG after a beef meal.
- Intravenous glucose caused prolonged elevations in plasma glucose and insulin in CRF patients.
- Elevated plasma glucagon in CRF patients was not suppressed to normal levels by glucose infusion and remained unchanged post-hemodialysis.
Conclusions:
- CRF patients display altered glucose and insulin dynamics, with a failure to suppress glucagon effectively.
- Chronic hemodialysis normalized glucose and insulin responses but did not resolve the elevated plasma glucagon in CRF.
- Impaired glucagon regulation may persist in CRF despite hemodialysis, independent of carbohydrate intolerance.
Related Concept Videos
Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Diabetic Nephropathy
Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...

